로딩 중…
지수 로딩 중…
KYUNG NAM PHARM.CO.,LTD.
053950· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,590+5.86%
2026-08-04
Financials
Valuation Metrics
KYUNG NAM PHARM.CO.,LTD.'s Market Cap is ₩312B. At end of 2025 it was ₩665B. Ranked #2039 of 2,436 in KR market (top 84%), #1295 of 1,649 on KOSDAQ (top 79%), #215 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 31.20B KRW | KR#2,039/2,436 Sec#215/234 |
| Revenue | 58.98B KRW | KR#1,690/2,436 Sec#114/234 |
| Net Income | -8.30B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 176.00B KRW | KR#1,364/2,436 Sec#102/234 |
| Net Assets | 125.39B KRW | KR#1,239/2,436 Sec#99/234 |
| Employees | 260 | KR#891/2,436 Sec#75/234 |
| Value | ||
| P/B | 0.25x | KR#221/2,436 Sec#6/234 |
| P/S | 0.53x | KR#982/2,436 Sec#43/234 |
| FCF Yield | -9.40% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -6.62% | KR#1,796/2,436 Sec#135/234 |
| ROA | -4.71% | KR#1,879/2,436 Sec#142/234 |
| Op. Margin | -2.48% | KR#1,772/2,436 Sec#122/234 |
| Revenue Growth | 23.18% | KR#586/2,436 Sec#56/234 |
| Financial Health | ||
| Debt Ratio | 40.37% | KR#144/2,436 Sec#19/234 |
| Total Debt | 35.51B KRW | KR#1,120/2,436 Sec#85/234 |
| FCF | -2.93B KRW | KR#1,388/2,436 Sec#107/234 |
| Cash | 21.93B KRW | KR#1,191/2,436 Sec#86/234 |
| Current Ratio | 1.75x | KR#1,121/2,436 Sec#120/234 |
| Performance | ||
| 1Y Return | -49.52% | KR#2,062/2,436 Sec#194/234 |
| 1M Return | -5.92% | KR#1,470/2,436 Sec#146/234 |
| From 52W High | -71.51% | KR#2,184/2,436 Sec#201/234 |
| 1Y MDD | -70.26% | KR#1,957/2,436 Sec#169/234 |
| Trading | ||
| Volume | 42,033 shares | KR#1,452/2,436 Sec#148/234 |
| Foreign Own. | 3.24% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -521 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,906 KRW | KR#1,193/2,436 Sec#85/234 |
Company Info
Kyungnam Pharm, established in 1998 and listed on KOSDAQ in 2001, adopted its current name after merging with HS Biopharm in 2010. The company manufactures and sells pharmaceuticals and health functional foods, distributing flagship products like Lemona nationwide through pharmacies and large supermarkets. It is expanding its business beyond its OTC specialist image, diversifying and growing the Lemona product line to increase sales and customer engagement through enhanced online marketing.